EMA Authorised: Hulio (adalimumab) — Biosimilar Collaborations Ireland Limited

View source ↗

Summary

The EMA authorised Hulio, a biosimilar of adalimumab, for multiple inflammatory indications including hidradenitis suppurativa, psoriasis, uveitis, rheumatoid a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Crohn Disease
• Hidradenitis Suppurativa
• Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis
• Uveitis

Drugs mentioned

• HULIO (ADALIMUMAB-FKJP)

Snippet

Status: Authorised. Therapeutic area: Hidradenitis Suppurativa;Psoriasis;Uveitis;Arthritis, Rheumatoid;Spondylitis, Ankylosing;Crohn Disease;Colitis, Ulcerative;Arthritis, Psoriatic. MAH: Biosimilar Collaborations Ireland Limited. Decision date: 17/02/2026